The role of humoral autoimmunity in the aetiology of achalasia.

The role of humoral autoimmunity in the aetiology of achalasia. - Antibodies in achalasia.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON37385

Enrollment

400

Registered

2012-04-03

Start date

2012-04-19

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Achalasia Oesophageal motility disorder

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with achalasia: - Diagnosis of achalasia confirmed by: - Oesophageal manometry; aperistalsis, LOS dysrelaxation and hypertensive LOS (>10mmHg). - Barium oesophagogram; delayed emptying, aperistalsis and dilatation of the oesophagus with narrowing of the distal oesophagus. - Eckhardt score * 2. - Age 18-75 years. - Written informed consent;Healthy controls: - Age 18-75 years. - Written informed consent

Exclusion criteria

Exclusion criteria: Patients with achalasia: - Pseudoachalasia - Chagas disease - Upper gastrointestinal malignancy;Healthy controls: - Symptoms suggestive of oesophageal disease. - History of malignancy. - History of diseases affecting the upper gastrointestinal tract (gastro-oesophageal reflux disease, eosinophilic oesophagitis) - Pseudoachalasia - Chagas disease - Autoimmune diseases

Design outcomes

Primary

Measure	Time frame
Difference in the presence of antimyenteric neuronal antibodies in patients with achalasia and controls.	—

Secondary

Measure	Time frame
- Identify the targeted antigen(s) of the antimyenteric neuronal antibodies. - General quality of life - Quality of life related to achalasia - Eckhardt clinical symptom score	—

Countries

Netherlands

Outcome results